智通财经APP获悉，荣昌生物(09995)跌超3%，截至发稿，跌3.01%，报12.26港元，成交额1466.79万港元。
消息面上，荣昌生物公布，预计2024年度营业收入约人民币17.15亿元，同比增加约58%；预计实现归属于母公司所有者的净亏损约14.7亿元，同比亏损减少约3%；扣非净亏损约14.98亿元，同比亏损减少约3%。公告称，本年度公司新药研发管线持续推进，多个创新药处于关键试验研究阶段，研发投入增加，同时泰它西普和维迪西妥单抗销售收入快速增长，产品毛利率持续增长，销售费用率明显下降。因此，预计公司2024年度为净亏损，呈减亏趋势，扣除非经常性损益前后均为亏损。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.